Jeffrey Matthews to Immunoconjugates
This is a "connection" page, showing publications Jeffrey Matthews has written about Immunoconjugates.
Connection Strength
0.252
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
Score: 0.202
-
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.
Score: 0.050